Cargando…

Integration of Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-Type Glioblastoma

Predictors of patient outcome derived from gene methylation, mutation, or expression are severely limited in IDH1 wild-type glioblastoma (GBM). Radiomics offers an alternative insight into tumor characteristics which can provide complementary information for predictive models. The study aimed to eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaddad, Ahmad, Daniel, Paul, Sabri, Siham, Desrosiers, Christian, Abdulkarim, Bassam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721570/ https://www.ncbi.nlm.nih.gov/pubmed/31405148 http://dx.doi.org/10.3390/cancers11081148

Ejemplares similares

Predicting survival time of lung cancer patients using radiomic analysis
por: Chaddad, Ahmad, et al.
Publicado: (2017)

Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation
por: Chaddad, Ahmad, et al.
Publicado: (2019)

Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma
por: Albert, Nathalie L., et al.
Publicado: (2023)

Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
por: de Groot, John F, et al.
Publicado: (2022)

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
por: Daniel, Paul, et al.
Publicado: (2019)

Feasibility, Safety and Impact on Overall Survival of Awake Resection for Newly Diagnosed Supratentorial IDH-Wildtype Glioblastomas in Adults
por: Moiraghi, Alessandro, et al.
Publicado: (2021)

SYST-08. A phase II trial of concurrent Sunitinib, Temozolomide and Radiation Therapy followed by adjuvant Temozolomide for newly diagnosed Glioblastoma patients with an unmethylated MGMT gene promoter (A01-M121-11A, McG1132)
por: Faye, Mame Daro, et al.
Publicado: (2021)

Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
por: Sasaki, Takahiro, et al.
Publicado: (2019)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Multi-scale radiomic analysis of sub-cortical regions in MRI related to autism, gender and age
por: Chaddad, Ahmad, et al.
Publicado: (2017)

Hippocampus and amygdala radiomic biomarkers for the study of autism spectrum disorder
por: Chaddad, Ahmad, et al.
Publicado: (2017)

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
por: Incekara, Fatih, et al.
Publicado: (2020)

Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis
por: Wende, Tim, et al.
Publicado: (2021)

Biological underpinnings of radiomic magnetic resonance imaging phenotypes for risk stratification in IDH wild-type glioblastoma
por: Guan, Fangzhan, et al.
Publicado: (2023)

MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
por: Hosseini, Seyyed Ali, et al.
Publicado: (2023)

Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients
por: Giunco, S., et al.
Publicado: (2023)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
por: Incekara, Fatih, et al.
Publicado: (2020)

Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma
por: Bagley, Stephen J, et al.
Publicado: (2021)

Diffusion tensor imaging‐based machine learning for IDH wild‐type glioblastoma stratification to reveal the biological underpinning of radiomic features
por: Wang, Zilong, et al.
Publicado: (2023)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease
por: Goldman, Jodi, et al.
Publicado: (2022)

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study
por: Caccese, Mario, et al.
Publicado: (2022)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Molecular landscape of IDH ‐wild type, pTERT ‐wild type adult glioblastomas
por: Liu, Emma Munan, et al.
Publicado: (2022)

Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma
por: Poon, Candice C., et al.
Publicado: (2019)

GEN-10 WHOLE GENOME LANDSCAPE OF GLIOBLASTOMA, IDH-WILD TYPE
por: Nakashima, Takuma, et al.
Publicado: (2022)

Implications of Cellular Immaturity in Necrosis and Microvascularization in Glioblastomas IDH-Wild-Type
por: Orasanu, Cristian Ionut, et al.
Publicado: (2022)

A vaccine targeting mutant IDH1 in newly diagnosed glioma
por: Platten, Michael, et al.
Publicado: (2021)

Analyses of metastasis-associated genes in IDH wild-type glioma
por: Li, Xiaozhi, et al.
Publicado: (2020)

Sex-specific radiomic features of L-[S-methyl-(11)C] methionine PET in patients with newly-diagnosed gliomas in relation to IDH1 predictability
por: Papp, Laszlo, et al.
Publicado: (2023)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

Assessment of Pre-operative Measurements of Tumor Size by MRI Methods as Survival Predictors in Wild Type IDH Glioblastoma
por: Palpan Flores, Alexis, et al.
Publicado: (2020)

Impact of CDKN2A/B, MTAP, and TERT Genetic Alterations on Survival in IDH Wild Type Glioblastomas
por: Hsu, Eric J., et al.
Publicado: (2022)

Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic
por: Bian, David J. H., et al.
Publicado: (2022)

Survival impact of delaying postoperative chemoradiotherapy in newly-diagnosed glioblastoma patients
por: Zhang, Maochen, et al.
Publicado: (2020)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
por: Marchi, Francesco, et al.
Publicado: (2020)

The Prognostic Value of NANO Scale Assessment in IDH-Wild-Type Glioblastoma Patients
por: Kasper, Johannes, et al.
Publicado: (2021)

Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma
por: Cao, Wenjun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g3m3p3q134mcrc2cutdgkdu6c1